



PROVIDING ANSWERS FOR CANCER PATIENTS

Press release

23 August, 2021

Curasight presents at HC Andersen Capital

Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the Interim Report First Half 2021 at HC Andersen Capital, 24 August 2021.

The presentation will be webcasted live 13:30 - 14:00 (CET), Tuesday 24 August 2021.

For more information – please [click here](#)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.